Aminoglycoside antibiotics are commonly used worldwide to treat gram-negative infections. They have proven efficacy and their safety profile is well recognized.
1 In high doses, or with protracted regimens, aminoglycosides cause nephrotoxicity and ototoxicity, the latter of which can manifest as either vestibulotoxicity or cochleotoxicity.
2 It was noted in the latter part of the 20th century that certain families have a predisposition to aminoglycoside-induced ototoxicity (AIO), whereby a single dose could cause profound and irreversible hearing loss.
3,4